secwatch.observer — SEC 8-K summary
======================================

Issuer:     Guardant Health, Inc. (GH)
CIK:        0001576280
Form:       8-K
Filed at:   2021-10-20T23:59:59+00:00
Accession:  0001193125-21-303088
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Guardant Health appoints Myrtle Potter to Board of Directors
------------------------------------------------------------

- Myrtle Potter appointed as Class I director effective Oct 15, 2021; term expires at 2022 Annual Meeting.
- Potter also appointed to audit committee; will receive standard non-employee director compensation.
- Compensation includes stock option and RSU each valued at $362,500 with modified grant date Nov 8, 2021.
- Awards vest 1/4 on first anniversary of appointment, then monthly over three years.
- Potter is CEO of Sumitovant Biopharma; previously COO at Genentech and President at Bristol-Myers Squibb.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576280/000119312521303088/0001193125-21-303088-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576280/000119312521303088/d242793d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-303088

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer